Samuel Duffey

BioVest International, Inc. develops and commercializes personalized therapeutic cancer vaccine for the treatment of B-cell blood cancers. The firm continued development, commercialization, manufacture and sale of AutovaxID and other instruments and disposables; and the commercial sale and production of cell culture products and services. The company was founded in 1981 and is headquartered in Tampa, FL.

Accentia Biopharmaceuticals, Inc. engages in the commercialization of patent-protected disruptive healthcare technologies. It offers products under the BiovaxID., Revimmune, and SinuNase brands. The company was founded in 2002 and is headquartered in Tampa, FL.

Analytica International, Inc. provides analytical and consulting services to the biopharmaceuticals industry. The company was founded on October 28, 2005 and is headquartered in New York, NY.

Hopkins Capital Group(Hopkins Capital) is a private equity firm founded in 1999 by Frank E. O'Donnell. The firm is headquartered in Tampa, Florida.

Vycellix, Inc. is a life science company that specializes in the development of cell and gene-based therapies for various medical conditions such as hematology/oncology, autoimmunity/chronic inflammatory diseases, and organ/tissue transplantation. The private company is based in Tampa, FL. The company's platforms were discovered by scientists at the Karolinska Institutet in Sweden, which is known for its Nobel Assembly. Vycellix is headquartered in the United States, with scientific operations in Sweden. The company's mission is to develop and commercialize optimized, next-generation T cell and natural killer (NK) cell-based cancer therapies using its transformational Vy-UC universal cell technology. The CEO of the company is Evren Alici.